Switch to:
More From Other Websites
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 21 2014
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts Nov 21 2014
Fighting kids' cancer, one voucher at a time Nov 21 2014
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
Sanofi touts new drugs but diabetes outlook disappoints Nov 20 2014
Regeneron & Sanofi Present Positive Data on PCSK9 Drug Nov 20 2014
Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
Regeneron Shares Could Reach $450 Nov 20 2014
Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
Sanofi eyes more than $38 bln from new drugs after CEO exit Nov 20 2014
The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Nov 20 2014
Sanofi, Regeneron eczema drug gets FDA fast-track designation Nov 20 2014
Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
The Forbes Healthcare Summit 2014: The Agenda Nov 19 2014
Regeneron/Bayer's Eylea Gets Japanese Approval for DME Nov 19 2014
3 Drugs Stocks Driving The Industry Higher Nov 19 2014
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab... Nov 19 2014
Stocks Boosted by Merck's Vytorin Data Nov 19 2014
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK